TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05897788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message Check-ins
Description: Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message Check-ins
Description: Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
Study: NCT05943938

Intervention type: OTHER
Intervention: Epic Sepsis Model Version - 1
Description: The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.

Intervention type: OTHER
Intervention: Epic Sepsis Model Version - 2
Description: The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.

Intervention type: OTHER
Intervention: Emory Sepsis Model
Description: Emory internal algorithm
Study: NCT06215196

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber Supplement Group
Description: Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
Study: NCT05825820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach Intervention (EOI) plus Care as Usual
Description: The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts.
Study: NCT05328973

Intervention type: OTHER
Group type: OTHER
Intervention: ELEQUIL
Description: patch placed on skin
Study: NCT05511246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venous ethanol
Description: Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Endocardial catheter ablation of VT substrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Endocardial catheter ablation of VT substrate
Study: NCT05988424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial mapping
Description: Creation of a left atrial voltage map

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial mapping
Description: Creation of a left atrial voltage map
Study: NCT06233539

Intervention type: OTHER
Intervention: Observational research without intervention
Description: Observational research without intervention

Intervention type: OTHER
Intervention: Observational research without intervention
Description: Observational research without intervention
Study: NCT04118868

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered using the Sofusa® DoseConnect™
Description: pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
Study: NCT06516822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI only
Description: After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
Study: NCT05496998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid™ TMVR TF System
Description: Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
Study: NCT05062148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Float-REST
Description: Subjects receiving Float-REST will float for 60 minutes three times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
Study: NCT04736758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 tablet
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 tablet
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study: NCT05991388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: CD20xCD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: CD-19-directed antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Modified R-ICE chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Modified R-ICE chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Modified R-ICE chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Modified R-ICE chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Modified R-ICE (Treatment Arm II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Modified R-ICE chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cells (TBC)
Description: Modified R-ICE chemotherapy
Study: NCT04763928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax+Decitabine
Description: Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes.
Study: NCT04673448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04968847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemaSeed Localized Directional Insemination
Description: Subjects undergoing FemaSeed Artificial Insemination
Study: NCT06479564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free weight training and machine training
Description: 20 participants will be in control group who will only perform free weight and machine training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: 20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
Study: NCT04844099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin Piperaquine
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin Piperaquine
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
Study: NCT04701060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
Description: preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Study: NCT06249789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
Study: NCT05380310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active SMART ANGEL solution
Description: Nurse intervention according to the alert level + traditional monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SMART ANGEL solution
Description: No alert + traditional monitoring + alert in case of imminent life threat
Study: NCT06249789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
Study: NCT04736758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study: NCT06443021

Intervention type: DEVICE
Group type: OTHER
Intervention: PD cycler
Description: After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP.
Study: NCT05348330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic intervertebral foramen block
Description: Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-point to pleura transverse process block
Description: Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
Study: NCT05646511

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SCRT
Description: 5x5 Gy: 25 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 5x5 Gy: 25 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX
Description: Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOXIRI
Description: Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
Study: NCT04077047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEngage
Description: The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
Study: NCT06461741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Dual-task EMG Biofeedback Training (EMG-BF)
Description: The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of \>1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the device is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles. In this trail is the Explore+ ExG amplifier which is sold by Mentalab.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Balance Exercise Training (BAL-EX)
Description: This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.
Study: NCT06098586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-managed exercise therapy program
Description: Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial wrist denervation
Description: AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
Study: NCT06011200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 1 dose of MCV4 on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSPV4
Description: 1 dose of MSPV4 on Day 0
Study: NCT05121207

Intervention type: DEVICE
Group type: OTHER
Intervention: Terahertz scanning
Description: Short scans using Terahertz device

Intervention type: DEVICE
Group type: OTHER
Intervention: Terahertz scanning
Description: Short scans using Terahertz device
Study: NCT06345105

Intervention type: DEVICE
Intervention: Endoscreener QC
Description: Artificial intelligence monitoring of effective withdrawal time
Study: NCT06321172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Bike
Description: Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
Study: NCT05625802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% ropivacaine
Study: NCT05144737

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Diabetes Prevention Program
Description: The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Diabetes Prevention Program
Description: The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
Study: NCT06458738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Printable denture base material
Description: The newly developed printable denture base material will be used for the production of dentures.
Study: NCT05939544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient
Description: Milk Fat Globule Membrane-enriched Powdered Ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control (Placebo) Powdered Ingredient
Description: Placebo Comparator: Control (Placebo) Powdered Ingredient
Study: NCT05386472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
Study: NCT04792099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
Study: NCT05386472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
Study: NCT06024382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: twin block
Description: 2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: twin block combined with low level laser
Description: 2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
Study: NCT06506942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study: NCT06458244

Intervention type: PROCEDURE
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy for AML consolidation treatment
Study: NCT05386472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
Study: NCT05767086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone antagonist (Cetrotide)
Description: clinical pregnancy rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (Tarlusal)
Description: clinical pregnancy rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: clinical pregnancy rates